News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IMPAX Laboratories, Inc. (IPXL) To Present At Goldman, Sachs & Co. 35th Annual Global Healthcare Conference


6/6/2014 7:08:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAYWARD, Calif., June 6, 2014 /PRNewswire/ -- Impax Laboratories, Inc.(NASDAQ: IPXL) invites investors and the general public to listen to a webcast of a discussion with Fred Wilkinson, President and CEO, and Bryan M. Reasons, Chief Financial Officer, at the Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 8:40 a.m. Pacific Time.

To listen to the live or archived webcast, visit the investor relations section of the Company's web site at http://investors.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Company Contact:
Mark Donohue
Investor Relations and Corporate Communications
(215) 558-4526
www.impaxlabs.com

SOURCE Impax Laboratories, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES